Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses

BACKGROUND: Despite development of several next-generation tyrosine kinase inhibitors (TKIs), crizotinib remains one of the first-line treatment options for advanced ALK-positive NSCLC and is widely used in situations where next-generation TKIs aren’t yet approved or economically inaccessible. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jianjiao, Li, Guodong, Yang, Xi, Chu, Li, Wang, Jialei, Li, Yida, Zou, Liqing, Li, Yuan, Xie, Congying, Zhu, Zhengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417092/
https://www.ncbi.nlm.nih.gov/pubmed/30866974
http://dx.doi.org/10.1186/s13014-019-1240-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417092/
https://www.ncbi.nlm.nih.gov/pubmed/30866974
http://dx.doi.org/10.1186/s13014-019-1240-1

Ejemplares similares